P&F Products and Features GmbH, the Austria-based cardiovascular device innovator, has secured approval from the U.S. Food and Drug Administration to initiate the TRICAV II pivotal clinical trial. The study will evaluate the TricValve Transcatheter Bicaval Valve System for severe tricuspid regurgitation, aiming to provide a minimally invasive option for patients who currently have no […]
Veradermics just completed pivotal trial enrollment for VDPHL01, its oral minoxidil for hair loss. Will it reshape dermatology? See what’s next.
FDA re-approves Augmentin XR under new priority program, restoring key antibiotic and signaling a turning point in U.S. drug supply strategy. Read more.
Pfizer’s tucatinib combo extends progression-free survival in HER2+ metastatic breast cancer. Find out what HER2CLIMB-05 means for frontline maintenance therapy.
Ascletis’ acne drug denifanstat advances with NDA acceptance in China. Explore how FASN targeting could disrupt acne care and redefine systemic treatments.
TrilliumBiO and Oncobit launch a ctDNA-based monitoring platform for uveal melanoma in the U.S. Learn how this could change rare cancer care in 2026.
Lilly’s Jaypirca reduced progression risk by 80% in frontline CLL. Explore what this changes for therapy sequencing, safety, and BTK inhibitor strategy.
Lilly’s Jaypirca met its Phase 3 target in CLL, matching Imbruvica on response rate and showing superior safety. Could this rewire frontline BTK therapy?
Medtronic’s Hugo robot gets FDA clearance for urology. Explore how it could reshape U.S. robotic surgery and challenge incumbent systems like da Vinci.
Philips expands LumiGuide AI 3D light-based navigation across US and Europe. Find out how it could reshape image-guided therapy without radiation.